Drug repositioning needs a rethink
نویسندگان
چکیده
منابع مشابه
Drug Repositioning in Cancer
The development of new therapeutic agents, in any kind of disease, requires either long time or high costs; indeed 10 15 years of research are required to market a drug, resulting in an overall cost of about 1.8 billion dollars [1]. In addition, drug development in oncology is very challenging due to cancer biological complexity, actually comprising several subtypes of diseases carrying differe...
متن کاملOrphan/rare drug discovery through drug repositioning
There are many, often life-threatening, rare/orphan diseases for which there are few or no therapeutic options. They individually affect few people, but collectively impose very high social and economic burdens. New approaches are bringing big pharma resources to solving the problem through drug repositioning of approved drugs. Advances are being spurred by public and private partnerships, gove...
متن کاملDrug Repositioning in Glioblastoma: A Pathway Perspective
Glioblastoma multiforme (GBM) is the most malignant primary adult brain tumor. The current standard of care is surgical resection, radiation, and chemotherapy treatment, which extends life in most cases. Unfortunately, tumor recurrence is nearly universal and patients with recurrent glioblastoma typically survive <1 year. Therefore, new therapies and therapeutic combinations need to be develope...
متن کاملA standard database for drug repositioning
Drug repositioning, the process of discovering, validating, and marketing previously approved drugs for new indications, is of growing interest to academia and industry due to reduced time and costs associated with repositioned drugs. Computational methods for repositioning are appealing because they putatively nominate the most promising candidate drugs for a given indication. Comparing the wi...
متن کاملDrug combination therapy increases successful drug repositioning.
Repositioning of approved drugs has recently gained new momentum for rapid identification and development of new therapeutics for diseases that lack effective drug treatment. Reported repurposing screens have increased dramatically in number in the past five years. However, many newly identified compounds have low potency; this limits their immediate clinical applications because the known, tol...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature
سال: 2016
ISSN: 0028-0836,1476-4687
DOI: 10.1038/535355d